The Value of Noninvasive Prenatal Screening for the Detection of Fetal Chromosome 16 Aneuploidy

Ting Wang,Jing Wu,Jiexia Yang,Jian Lu,Li Guo,Li Du,Aihua Yin
DOI: https://doi.org/10.3760/cma.j.issn.1003-9406.2020.02.008
2020-01-01
Abstract:OBJECTIVE:To assess the value of non-invasive prenatal screening (NIPS) for the detection of fetal chromosome 16 aneuploidy through multi-method verification and follow-up of pregnancy outcomes.METHODS:From January 2016 to December 2017, 7972 pregnant women with singleton pregnancies accepted the NIPS test after 10th gestational week with informed consent. Those with fetal chromosome 16 abnormality suggestive by the NIPS test were subjected to prenatal diagnosis including chromosomal karyotyping and chromosomal microarray analysis (CMA).RESULTS:Of the 7972 pregnant women tested by NIPS, 16 (0.2%) were predicted to have fetal chromosome 16 abnormality. The average age of the 16 pregnant women was 33.5 ± 5.24, and the average gestational week was 19.88±2.47. Chromosomal karyotyping verified that 3 fetuses had mosaicisms and 1 carried pericentric inversion of chromosome 9, which yielded a positive predictive value (PPV) of 18.8%. CMA has detected 7 fetuses with genomic abnormalities, which yielded a PPV of 43.8%. Eleven of the 16 women (68.8%) have given birth to healthy babies.CONCLUSION:For pregnant women with a high risk of chromosome 16 aneuploidy suggested by NIPS, the prognosis of fetus should be evaluated by multiple methods. Compared with conventional karyotyping analysis, molecular methods such as CMA are far superior.
What problem does this paper attempt to address?